genesistogether we can transform patient care. find out more at johnson & johnson innovation...

genesis 2013Conference Handbook 2013

Designed to foster scientific creativity and encourage entrepreneurship among clinicians and researchers, BioQuarter combines world-class research from Edinburgh University’s College of Medicine and Veterinary Medicine with the long tradition of clinical excellence at NHS Lothian. Building one of Europe’s most significant concentrations of clinical and research assets, BioQuarter brings together a major teaching hospital, medical school and three leading research institutes in one location. Our seasoned business development team has spun out four new businesses and negotiated four major industrial collaborations in less than two years, as well as generating 100 new product or business concepts from its innovation competition.

To find out more about how this commercialisation partnership is building on Scotland’s successes in life sciences, visit www.bioquarter.com

EDINBURGH LAUNCHES WORLD’S FIRST VISUAL FIELD ANALYSER FOR CHILDRENIn March 2012, Edinburgh BioQuarter launched i2eye Diagnostics Limited, creators of the world’s first visual field analyser for children and hard-to-test patient groups. Based on research undertaken at the University of Edinburgh and NHS Lothian, this device enables young children’s field of vision to be tested accurately for the first time, helping to pick up retinal and optic nerve defects as well as certain forms of brain cancer. Backed by private venture capital,

the company has booked its first orders and is set to take premises in our new incubator building, Nine the BioQuarter: www.i2eyediagnostics.com

WELCOME TO EDINBURGH BIOQUARTER

ContentsGenesis 2013 Sponsors

Corporate Patron

Corporate Sponsors

Partners

Media Partners

Gold Sponsors

Silver Sponsors

Bronze Sponsors

Case Study Sponsors

Supporters Wifi Sponsor

3

Welcome 7 Keynote Speakers 8 - 9 Speaker Profiles 9 - 21

Programme 22-23

Floor Plan 24 Exhibitor List 25

The Genesis Talent Lounge 27

Exhibitor Profiles 31- 42

ON Hub 43

Sponsors

SCOTLAND. SUCCESS LIKES IT HERE.

To hear what we can do for you, visit us at Genesis, Stand 6

We’ve got quite a reputation for invention, innovation

and improving people’s lives. Penicillin. Keyhole

surgery. The beta-blocker. The game of golf. It’s a

long list. And it’s still growing. In every sector from

fi nance and electronics to our pioneering work in life

sciences, we strive to set standards. We have world-

class academic institutions and purpose built science

parks with some of the fi nest research facilities in

the world. And passionate people with a hunger

to win. We can develop your products and expand

your business. And that’s precisely why companies

invest in Scotland.

We’re the toast of the scientifi c community.

Scotland.The home of Whisky and the Bionic Hand.

© Johnson & Johnson Innovation, a division of Johnson & Johnson Finance Ltd. 2013www.jnjinnovation.com

Johnson & Johnson Innovation is positioned at the heart of the world’s most creative science hubs. We contribute to the life sciences ecosystem by being an integral member of regional scientifi c communities and taking a new approach to partnering to advance early-stage innovation. Our goal: translate cutting edge ideas into healthcare solutions for patients.

Together we can transform patient care. Find out more at www.jnjinnovation.com

Johnson & Johnson Innovation CentersA new approach to advancing early-stage innovation

BOSTON

CALIFORNIA

LONDON

SHANGHAI

JJIC_1pageAd_WBT2013_A4_v3.indd 1 11/14/13 10:41 AM

SCOTLAND. SUCCESS LIKES IT HERE.

To hear what we can do for you, visit us at Genesis, Stand 6

We’ve got quite a reputation for invention, innovation

and improving people’s lives. Penicillin. Keyhole

surgery. The beta-blocker. The game of golf. It’s a

long list. And it’s still growing. In every sector from

fi nance and electronics to our pioneering work in life

sciences, we strive to set standards. We have world-

class academic institutions and purpose built science

parks with some of the fi nest research facilities in

the world. And passionate people with a hunger

to win. We can develop your products and expand

your business. And that’s precisely why companies

invest in Scotland.

We’re the toast of the scientifi c community.

Scotland.The home of Whisky and the Bionic Hand.

The route to new markets new funding new ideas

Go further, faster

www.een-london.co.uk || [email protected] || +44 (0) 20 7940 1512

Enterprise Europe Network London

Harriet Fear CEO, One Nucleus

Welcome

Lucky for all of us I hope! The One Nucleus team and I know you will make full use of the presentations, debate, networking and the exhibition hall to catch up with old friends and make some new ones, update yourselves on trends in the sector and create and scope out new business opportunities.

I know times continue to be tough for many of you. As I always maintain, however, there have always been a myriad of challenges for companies in this environment and you have always had to think creatively to forge ahead. The sector has many champions, exceptional entrepreneurs and individuals who are well placed to meet the challenges and continue to strengthen the sector into the future. Many of them are here today.

Here at One Nucleus we continue to enhance our offer to our members and the sector at large. At the heart of our strategy are two key threads:

• To work collaboratively with other organisations and cut down the duplication of efforts to support our members and

• To create connections with international organisations who can help our members with their global growth and competitiveness

The One Nucleus membership continues to grow and we remain the largest membership organisation in Europe (by some distance, with over 470 organisations as members). The majority of our members are based in Cambridge and London.

Genesis 2013 continues to be a truly international networking exhibition. We are delighted that UK Trade & Investment has chosen to repeat the success of their UKTI International Zone that we have brought in for the last two years and you will find it again this year in the Fleming Room. Commercial Officers (many of them specialists in the sector) have joined us from around the world and are ready to provide you with information, contacts and ideas in the partnering zone – all free and impartial. New for this year is our Talent Lounge - do check out Page 27 for more details.

We are also continuing with the much appreciated (by us and delegates) collaboration with the SCRIP team on Genesis, which saw its first ‘outing’ at Genesis 2012. We have worked incredibly closely together on key elements of the event, evolving it to enhance the knowledge sharing opportunities. The insights gained over the day will fuel the much anticipated Plenary Debate providing the panellists and delegates with the chance to share their suggestions to enhance success at individual, company and sector wide level.

I wish everyone an excellent event.

welcomeDear Genesis 2013 Participant,

Welcome to our 13th Annual Genesis Conference:

The route to new markets new funding new ideas

Go further, faster

www.een-london.co.uk || [email protected] || +44 (0) 20 7940 1512

Enterprise Europe Network London

7

Dr Louise WoodDeputy Director/Head of NHS Research Infrastructure and Industry R&D Relations, R&D Directorate , Department of Health Louise is Deputy Director/Head of NHS Research Infrastructure and Growth in the Research and Development Directorate of the Department of Health and a member of the Directorate’s Senior Management Team. She has oversight responsibility for the NIHR-funded clinical research infrastructure in the NHS and partner universities and for the NIHR Office for Clinical Research Infrastructure (NOCRI). She co-chairs the Ministerial Industry Strategy Group (MISG) Clinical Research Working Group and is involved in all the major Government/industry/NHS initiatives established to improve the research partnership between the NHS, its university partners and the life sciences industries, including the Office for Life Sciences

Sir Salvador MoncadaProfessor of Experimental Biology and Therapeutics, Wolfson Institute for Biomedical Research, UCL

Salvador Moncada, MD, obtained his PhD in 1973 at the Royal College of Surgeons in London. He then moved to the Wellcome Research Laboratories where he initiated the work leading to the discovery of the enzyme thromboxane synthase and the vasodilator prostacyclin. He was also responsible for the identification of nitric oxide as a biological mediator and the elucidation of the metabolic pathway leading to its synthesis. Since 1996 Professor Moncada has directed the Wolfson Institute for Biomedical Research at University College London. He continued his research in the areas of mitochondrial biology and cell metabolism where he made significant contributions. His current research is concentrated in the area of cell proliferation. Professor Moncada is a Fellow of the Royal Society and a Foreign Associate of the National Academy of Science of the USA and in 2010 he received a Knighthood for his services to Science.

Mike WardGlobal Director of Content, SCRIP Intelligence Mike has been writing, analysing and commenting on the life sciences industry for the past 30 years. He has focused on business models, R&D strategies and how to finance innovation, and is often called upon by the industry’s key stakeholders to provide thought leadership. In 2010 he was named European Mediscience Commentator of the Year.

Roel BulthuisSenior Director, Head of Merck Serono Ventures at Merck Serono

Roel Bulthuis is Head of MS Ventures, the strategic venture capital fund of Merck Serono, which he established in 2009. MS Ventures also manages the Merck Serono Israel BioIncubator Fund and the Merck Serono Entrepreneur Partnership Program. Previously, Roel was a Director in the Biotech Investment Banking Team at Fortis Bank, based out of Amsterdam and New York. Before that, he worked at Devgen in Ghent, Belgium. Roel holds a Msc. in Biopharmaceutical Sciences from Leiden University, the Netherlands, and an MBA in Finance from the Helsinki School of Economics, Finland.

8 Keynote Speakers

Speaker Profiles

Mohammad Afshar, President and CEO of Ariana Pharmaceuticals, founded the company in 2003. Prior to this, Mohammad was a founder and the Director of Drug Design and IT at RiboTargets, Cambridge, UK. Before that, Mohammad held several positions in academic institutions including at the University of York, UK, and the CRBM of the CNRS in France. He holds a Medical Degree (DCEM), MPhil in Computer Science (DEA), and a PhD in structural biochemistry.

Session: Developing Oncology Biomarkers: Lessons from other Therapeutic Areas

Mohammad AfsharCEO, Ariana Pharmaceuticals

Mo Alavijeh is a bioentrepreneur with >20 years experience in the pharmaceutical industry covering wide range of responsibilities, including R&D, innovation, business development and strategic alliances. His specialist expertise is CNS DMPK, with distinctive competence in neuro-pharmacokinetics. Prior to co-founding Pharmidex, Mo was head of drug metabolism, pharmacokinetic and pharmacodynamic (DMPK/PD) at Vernalis Research, before which he was DMPK team leader at Aventis Pharma. He studied for his PhD at the Institute of Neurology, London.

Session: Imaging in CNS

Mo AlavijehCEO, Pharmidex

John Ansell is the kingpin of TranScrip’s business development, covering due diligence, life-cycle planning, product evaluation, business plans and forecasting. He has 20 years of experience in the pharmaceutical industry, followed by over 20 years as a consultant to biotech and pharma companies as well as those providing services to the industry. John is the author of Transforming Big Pharma – Assessing the Strategic Alternatives (Gower Publishing, 2013) as well as of numerous articles on pharma deals.

Session: Approaches to Partnering - Part I

John AnsellSenior Partner, TranScrip Partners

Professor Sir Christopher Evans OBEChairman, Excalibur Group

Founder and Chairman of Excalibur Group, Sir Chris is a highly successful scientist and entrepreneur with numerous prestigious awards and medals for his work. He has built over 50 medical companies from scratch, many from his own ideas and inventions and floated 20 new medical businesses on stock markets in six different countries. Sir Chris has created companies worth over $6 billion employing over 4,000 scientists and built 100s of complex medical laboratories and facilities around the world and positively impacted many millions of lives with his work. He has also raised $2billion for cancer research projects. Founder of Chiroscience, Celsis, Biovex, Merlin, Vectura & and Piramed.

9Keynote Speaker

Speaker Profiles

Martin Buckland has served as Chief Business Officer of Astex since September 2004. He has more than 25 years of commercial and business development experience in the pharmaceutical industry and joined Astex from Elan Pharmaceuticals, where he previously held the position of Vice President of Global Business Development. His prior experience includes a variety of business development and commercial management roles with Quintiles, Xenova and Celltech.

Session: Case Study 3 - Astex Pharmaceuticals and Otsuka

Martin BucklandCBO, Astex

Dr Eddie Blair is Managing Director of Integrated Medicines Ltd (IML), a company he formed in 2003 to enable personalised medicine by combining diagnostic-type testing with new and existing medicines. He is also a non-executive director (Rem Com Chair) of Immunodiagnostic Holdings PLC, founding director of Integrated Magnetic Systems Ltd (IMSL), and a visiting scholar to the Cambridge University Masters in Bioscience Enterprise programme. He also lectures on personalised medicines and offers occasional bespoke courses based on his best-selling books.Eddie has published more than 40 primary, peer-reviewed papers, including a series on companion diagnostic valuation, and is editor of two personalised medicine journals. Finally, he is named inventor on at least one dozen patents, including tuneable magnetic proteins, the technology being exploited by IMSL.


Dr Eddie BlairManaging Director, Integrated Medicines

Dr. Morris S. Berrie is the Co-Chairman of TTS Ltd. and Managing Director of Tech Investor Ltd. The former globally facilitates deal flow in the tech transfer / early stage / SME biotech sector whilst the latter advises on ‘the business of science’, i.e. strategic business development and capital raising. Previously he has been CEO at Biotechnology Investment Group, Head of Intelligence at NPG, a Director at Thomson Reuters, and worked at GlaxoWellcome and Schering AG.


Morris BerrieManaging Director, Tech Investor

Steve joined the BIA as its Chief Executive Officer in July 2012. Steve Bates has worked both in biotech and the highest levels of UK government for 15 years. He was Senior Director, External Affairs and Market Access at Genzyme UK and Ireland, during which time he worked on the establishment of the Office for Life Science and was a member of the BIA’s Communications Advisory Committee. Previously Steve was special advisor to John Reid MP in his time as Home Secretary, Secretary of State for Health, Northern Ireland Secretary and Defence Secretary, helping deliver various policy initiatives including the implementation of the Serious Organised Crime Act of 2005.Earlier in his career Steve led the Labour Party media team into the general election of 2001 and was formerly a broadcast business journalist at Dow Jones and ITN. Steve is a Cambridge University graduate.

Session: Life Science Manifesto 2015-20

Steve BatesCEO, BIA

Davidson Ateh is an entrepreneur operating in the life sciences. He has an interdisciplinary scientific background in bioengineering and was a past recipient of the prestigious Royal Society of Edinburgh/BBSRC Enterprise Fellowship. He has won awards for his scientific and commercial activities. Davidson Ateh is the CEO of BioMoti, seeking to transform the treatment of cancer by targeted delivery of therapeutics to the intracellular space of cancer cells.

Session: Case Study 4 - Ipsen and Syntaxin

Davidson AtehCEO, BioMoti

10 Speaker Profiles

James CaanCEO, Hamilton Bradshaw

James Caan is one of the UK’s most successful and dynamic entrepreneurs. He made his fortune in the recruitment industry, which included the global success of his companies, Alexander Mann Group and Humana International, and he has been building and selling businesses ever since. In 2004 he founded private equity firm Hamilton Bradshaw based in London’s Mayfair. The company specialises in buyouts, venture capital, and real estate and now manages a portfolio of over 30 companies. James is best known for joining the panel of the hit TV show on BBC, Dragons’ Den, where he invested in 14 companies and committed over £1m of investment, over 4 series. In 2012, he was approached by CNBC to host The Business Class, a series which sees him joined by experts from a cross section of industries, looking at the challenges and opportunities faced by UK SMEs. Each 30 minute episode featured an innovative business which was seeking guidance to help it grow in the market place. The popularity of the series saw it re- commissioned for a second series in October 2013.James has written three best-selling books - his autobiography The Real Deal, Get the Job You Really Want and Start Your Business in 7 Days. Get the Job is based on his 30 years in the recruitment industry and reached No. 1 in 3 categories on Amazon, as well as becoming the best-selling practical business book of 2011. In Start Your Business, James uses his experience to help the new generation of entrepreneurs work out if their business ideas are workable and bankable. The book reached No. 2 in the Amazon business chart within two weeks of launching.James is extremely passionate about supporting small businesses and launched a free app, James Caan Business Secrets to help other entrepreneurs on their journey to success. The app was the fastest downloaded business app of 2011 and is regularly ranked in the Top 100 apps ever in Apps Magazine, with over 200,000 downloads to date.

Session: The SCRIP - One Nucleus Debate

In his role as President & CEO of BIOTECanada Andrew is responsible for the day-to-day operations of the Association. In this capacity, he is the primary spokesperson for Canada’s biotech industry communicating on the industry’s behalf with government, regulators, international bodies, media and the Canadian public. He also ensures BIOTECanada plays a central role in partnership with Government in the development of policy relating to Canada’s biotech sector and the member companies of BIOTECanada. Prior to joining BIOTECanada, Andrew served from 2004-2012 as Vice President, Public Affairs and International Trade and Vice President, Government Relations and Communications for the Forestry Products Association of Canada. In those roles he held responsibility for the Association’s government relations, communications, media relations, advertising and international trade undertakings. From 1993-2004 he held the position of Assistant Vice-President, Government Relations with the Canadian Life and Health Insurance Association. Between 1989 and 1993 Andrew held political assistant positions with a Member of Parliament and the Minister of State (Finance).Andrew Casey is a native of Montreal, Quebec. After attending Loyola High School (Montreal) and St. Lawrence CEGEP (Quebec City) he graduated from Carleton University (Ottawa) with a Bachelor of Arts degree in Political Science.

Session: Natural Product Development

Andrew CaseyPresident and CEO, BIOTECanada

Currently VP Endocrinology, Corporate Business Development working for a mid-sized French based pharma company, Ipsen. A highly motivated business development professional with a successful track record of identifying and delivering value-generating opportunities. Previously part of the Neurology team within Ipsen focusing on botulinum toxin development, registration and new toxin opportunities. A broad experience of BD, Alliance Management, Clinical Development, Regulatory Affairs and Project Management within small, medium and large pharmaceutical companies. Trained originally as a pharmacist and now has more than 30 years experience within the pharmaceutical industry.

Session: Case Study 4 - Ipsen and Syntaxin

Helen CohenSenior Director, Neurology, Corporate Business Development, Ipsen

11Speaker Profiles

Désiré Collen holds an MD degree and a PhD degree in Chemistry from the University of Leuven (KULeuven), Belgium. He was director of the Center for Molecular and Vascular Biology of KULeuven, and of the Vesalius Research Center of the Flanders Institute for Biotechnology (VIB) in Leuven, Belgium. His research groups initially developed t-PA for treatment of heart and ischemic stroke (with Genentech Inc) and microplasmin for symptomatic vitreomacular adhesion (sVMA) (with ThromboGenics NV). He was founder and chairman of ThromboGenics NV. He was awarded nobility status by King Albert II of Belgium in 2012 and honorary citizenship of Sint-Truiden, Belgium (his birthplace) in 2013.

Session: Case Study 2 - ThromboGenics and Novartis

Professor Dr Désiré Collen Chairman and Founder, ThromboGenics

Experimental medicine and ‘fast-to-fail’ are important concepts in improving R&D productivity. Molecular and multi-modal imaging can provide early information in-man on disease processes, drug-target engagement and dosing, which help to reduce risks in early-stage drug development. Imanova, a novel JV between the MRC, UCL, ICL and KCL, was established to drive innovation in imaging sciences. We offer a comprehensive range of services, including novel probe development, pre-clinical PET imaging, clinical PET and MRI and full quantitative analysis. With our pharmaceutical company pedigree and world-class science base, we understand drug development and the importance of collaboration, high quality and hitting deadlines Specialities: Neuroscience, Oncology, Inflammation, Respiratory, Infectious diseases, Translational Medicine.


Kevin CoxCEO, Imanova

Greer Deal MCMI MTOPRA, Director of Global Regulatory Services, has an extensive career in the pharmaceutical industry. Her experience includes regulatory affairs, medical information, pharmacovigilance, product development and compassionate use programmes. Greer is passionate about plant-derived products and believes Pharma needs to ‘look back’ in order to go forward and that investors must be bold to help revolutionise this niche area of the life sciences.


Greer DealDirector, Global Regulatory Services

Dr Barbara Domayne-Hayman has a broad range of commercial, fund-raising and general management experience, with many years of business development. She is currently ‘Entrepreneur-in-residence’ at the Stevenage Bioscience Catalyst and Chief Business Officer at Autifony Therapeutics.Previously, Barbara was CEO of Stabilitech, a platform technology company stabilising vaccines and other biologics, for four and a half years. She raised funding, including considerable amounts from non-dilutive sources such as the US Department of Defense as well as the UK’s Technology Strategy Board, established multiple commercial collaborations and built the team from very early stage. Prior to this, she was Commercial Director at Arrow Therapeutics, an antiviral drug discovery and development company, for over four years, until the company was acquired by AstraZeneca in 2007. Before working at Arrow, Barbara was Senior Business Development Manager at Celltech. She previously held senior international commercial positions at Zeneca where she worked for over ten years. She has also consulted in Life Sciences for Ernst & Young Strategy Group, and holds a Sloan Fellowship from London Business School. She has a BA and D.Phil in chemistry, from the University of Oxford.


Dr Barbara Domayne-HaymanEntrepreneur-in-residence, Stevenage Bioscience Catalyst and Chief Business Officer, Autifony Therapeutics

12 Speaker Profiless

Dr Neil Fish is currently Director, Business Development at Norgine and is responsible for in-licensing new opportunities. Prior to this, he was a co-founder of Alizyme plc and was a key part of the team which took the company from start up to a full LSE quoted company. He had a number of key roles including in and out licensing, research manager and was responsible for the companies IP portfolio. Neil was a part of the team that discovered cetilistat (a novel lipase inhibitor to treat obesity), conducted its clinical development and out-licensed the Japanese rights to Takeda. Cetilistat should be launched in Japan in 2014.

Session: Case study 4 - Ipsen and Syntaxin

Flic is one of TranScrip’s specialists in infectious disease, respiratory, renal disease and a pre and peri-registration drug safety expert. She has worked in the industry for more than 30 years and has held a number of senior and CEO positions in both pharma and CRO companies.Flic has worked for pharma and bio-tech companies in Europe and North America on a range of projects including NCEs and biological.

Session: Approaches to Partnering - Part I and II

Flic GabbayFounder and Partner, TranScrip Partners

Susan Foster, a Member in Mintz Levin’s London office, works with life sciences companies on data protection matters and agreements relating to research, development and commercialisation. She is qualified in England & Wales as well as California. Susan earned an A.B., with highest honors, from Princeton University (1989), a Ph.D. from Cornell University (1997), and a J.D., with distinction, from Stanford Law School (2000).


Susan FosterMember, Mintz Levin

Matthew joined SR One in 2011 to take the lead in investing SR One’s UK biotech fund. Prior to joining SR One he worked as a consultant for Longbow Capital Partners in London. Before that he was a Vice President of Greenhill & Co, an M&A Investment Bank and Private Equity firm, where he worked for eight years up until 2010 in New York.

Matthew holds a BSc / MA in molecular biology from St Peter’s College, University of Oxford; a Certificate in Corporate Finance from The London Business School and various FSA & SEC qualifications.

Session: SCRIP - One Nucleus Debate

Matthew FoyPartner, SR One

Dr Neil Fish Director, Business Development, Norgine

13Speaker Profiles

Accountabilities: Vice President Business Development Operations; leading AstraZeneca’s transaction execution, due diligence and Alliance and Integration Management function including early and late stage and on-market licensing and partnering, M&A, and divestments.Career background: ICI, Zeneca, AstraZeneca roles in Corporate, Pharmaceuticals and US Legal departments, HR and Business Development.Major Projects: AZ Merger, Creation of Avecia and Syngenta, Acquisition of CAT, MedImmune and Amylin, Spin out of Albireo.

Session: Case Study 1 - AstraZeneca and Bristol Myers Squibb The SCRIP – One Nucleus Debate

Shaun GradyVice President - Strategic Partnering & Business Development, AstraZeneca

Dr. Gestrelius is the founder and CEO of the Knowledge Building company Capish. Capish is specialising in using computers for speeding up the knowledge development within multi-disciplinary projects of pharmaceutical R&D. Focus is on complicated projects and Personalised Medicine. Prior to founding Capish Dr. Gestrelius founded and served as CEO of QlikTech (Nasdaq: QLIK) during the company’s first six years. Dr. Gestrelius was born in Malmö, Sweden, and is a graduate from the University of Lund, Sweden. He is a Master of Science in Technical Physics and Associate Professor in Medical Physiology. He was a pioneer in the simulation of complex biological processes in the 1980-ies. Dr Gestrelius interest in using computers to improve research processes took him to AstraZeneca R&D where he served as IT Director for seven years, before co-inventing the interactive graphical interface QlikView, which is the flagship product of QlikTech.Specialties: Clinical data warehousingOntology designPatient-centric modelling.

Session: Data Management in Healthcare Research

Staffan GestreliusFounder and CEO, Capish

Partnering for scientifi c leadership

astrazeneca.com/partnering

3618_Partnering_Ad_2013_A4.indd 1 27/09/2013 15:43

Dr Matthias Grossmann MD, PhD provides a broad range of expert consulting services for Early Drug Development. He has more than 13 years of industry experience in Drug Development. He worked in academia from 1980 to 2000, at the Humboldt University in Berlin, the University of Texas Health Science Centre in San Antonio, the Stanford University School of Medicine and the Technical University of Dresden. He is board certified in Clinical Pharmacology, Clinical Physiology and Pathophysiology.

Session: Monoclonal Antibody Therapeutics

Matthias Grossmann Vice President and Principal Consultant, Early Phase Medical Affairs and Consulting, PAREXEL International GmbH

Steve GardnerPartner, Biolauncher and CEO, RowAnalytics


Steve has built a number of innovative informatics technologies, products and companies in life sciences and healthcare in the US, UK and Europe. He has consulted widely to pharma, biotech, venture firms, the NHS and Government and built consortia in digital health, stratified medicine, biobanking and drug discovery. Steve was previously CTO of BioWisdom, CEO of Synomics and Astra’s Director of Research Informatics.

14 Speaker ProfilesSpeaker Profiless

Partnering for scientifi c leadership

astrazeneca.com/partnering

3618_Partnering_Ad_2013_A4.indd 1 27/09/2013 15:43

Speaker Profiles

Ansar JawaidDirector Personalised Healthcare & Biomarkers, AstraZeneca


Ansar has worked in pharmaceutical R&D and commercialisation at AstraZeneca for 11 years. His particular area of expertise is in personalised healthcare across therapeutics, diagnostics and healthcare I.T. He drove the global commercialisation of companion diagnostics for the first lung cancer personalised medicine IRESSA and is currently launching the first ovarian cancer personalised medicine Olaparib in EU and US, with leadership of companion diagnostics globally. Ansar developed AstraZeneca`s personalised healthcare footprint in Asia and Europe and worked on R&D and commercialisation of therapies across therapeutic areas. Ansar has led teams to pioneer genetics and genomics to discover companion biomarkers, rescue drugs, and identify therapeutic targets across oncology, cardiovascular, respiratory and CNS areas. Ansar holds a PhD in Genetics and has published over 20 scientific articles and inventor of four biomarker patented invention.

Harren Jhoti, PhD, has served as president and member of the Board of Directors since July 2011. He co-founded Astex Therapeutics Limited in 1999 and was chief scientific officer until November 2007 when he was appointed chief executive. Dr. Jhoti was awarded the Prous Institute-Overton and Meyer Award for New Technologies in Drug Discovery by the European Federation for Medicinal Chemistry in 2012 and was also named by the Royal Society of Chemistry as “Chemistry World Entrepreneur of the Year” for 2007. He has published widely including in leading journals such as Nature and Science and has also been featured in TIME magazine after being named by the World Economic Forum a Technology Pioneer in 2005. Dr. Jhoti previously served as a non-executive director of Iconix Inc. and currently serves on the board of the BIA, the UK BioIndustry Association. Before founding Astex Therapeutics in 1999, he was head of Structural Biology and Bioinformatics at GlaxoWellcome in the United Kingdom (1991-1999). Prior to Glaxo, Dr. Jhoti was a post-doctoral scientist at Oxford University. He received a B.Sc. (Hons) in Biochemistry in 1985 and a Ph.D. in Protein Crystallography from the University of London in 1989.


Harren Jhoti CEO, Astex Pharmaceuticals

Before its acquisition by Gilead Sciences, Dr Kennard was VP, Strategic Alliances YM BioSciences Inc. having joined that Corporation in 2004. Prior to joining YM, he was CEO of NeuroTargets, focused on novel treatments for nerve injury and pain. Dr. Kennard spent eight years prior to that as the COO of SR Pharma, a publicly traded UK-based biotechnology company which developed therapeutic vaccines. He was also with GlaxoSmithKline in development and then strategic planning roles.


David KennardAdvisor, Corporate Development, Gilead Sciences

John has been a commentator and participant in biotechnology and life sciences research for over three decades as a writer and consultant. His focus has been on the use of deep data of all kinds to dispel market myths and redirect efforts in early commercial decision-making.

Session: Case Study 2 - ThromboGenics and Novartis Case Study 4 - Ipsen and Syntaxin The SCRIP – One Nucleus Debate

John HodgsonManaging Editor, SCRIP Intelligence

16 Speaker Profiles

Mr Meredith Lloyd-Evans is founder of BioBridge Ltd and a Partner of the EU’s PharmaSea project which will overcome the bottlenecks in productive marine biodiscovery. BioBridge assists clients in all aspects of the innovation chain from research through start-ups to established companies, including practical project-related assistance and longer-term strategic support and analysis. Current activities include marine and industrial biotechnology and renewables, and long-term support for pharma & biomaterials companies and government agencies.


Meredith Lloyd-EvansFounder, BioBridge Ltd

Emily Liang joined UK Trade and Investment at the British Consulate-General Guangzhou in 2005. For the past 8 years, Emily has focused on the Life Sciences sector (which includes medical devices and biopharm) and has worked with the UKTI team assisting UK companies, such as Alliance Boots, IDC etc, to successfully develop business in southern China. Emily has developed an extensive network of contacts in southern China’s medical sector.

Session: UKTI Showcase

Emily LiangSenior Trade and Investment Officer, UKTI China

David Mackie is a founding director of Marine Biopolymers, a Scottish based company which is pioneering the re-introduction of commercial scale manufacture of marine origin polymers in the UK, with an especial emphasis on indigenous seaweeds as the key feedstock. Very experienced and has a long background in senior management and marketing positions in both the chemical industry and the forest products industry.


David MackieDirector, Marine Biopolymers

John Maclennan is Vice Consul, Trade and Investment Officer and USA sector lead for the Pharmaceutical and Biotech market sectors. Based in Boston, John works with US companies to help them understand that the UK is a good place to run clinical trials, establish European headquarters and to leverage UK government initiatives in stratified medicine, cell therapy and dementia and other neurological conditions. He also consults with UK companies on their international business strategy, and helps them commercialise their services and products in the US market. John has a Ph.D. from Edinburgh University in structural biology and an MBA with a ‘high tech’ focus from Northeastern University.


John MacLennanVice Consul, Trade and Investment Officer and USA Sector Lead, UKTI

Following medical school, Dr. Klein started postdoctoral fellowships at the Dept. of Physiology (Munich) and the National Heart, Lung and Blood Institute (Bethesda, MD) working on the genetics of lipid disorders. He then joined the Dept. of Clinical Chemistry (Munich) and founded Medigenomix, now part of Eurofins. Dr. Klein also founded the Center of Human Genetics and Laboratory Diagnostics (Martinsried) and IMGM Laboratories. He is author of numerous publications and serves as a field editor for the Journal of Laboratory Medicine.


Dr Hanns-Georg Klein, M.D.CEO, IMGM Laboratories GmbH

17Speaker Profiles

John O’Brien is Professor of Old Age Psychiatry in the Department of Psychiatry at the University of Cambridge, having previously been Professor at Newcastle University. His research interests are in dementia and depression in later life, especially the application of imaging biomarkers for diagnosis and monitoring disease progression.He was a member of the NICE Dementia Guidelines Group, is Past President of the International College for Geriatric Psychoneuropharmacology, an NIHR Senior Investigator and the National DeNDRoN Research Lead for Dementia in England.


John O’BrienProfessor of Old Age Psychiatry, Department of Psychiatry, University of Cambridge

Hitomi Nakai is responsible for trade promotion of the UK biotech/pharmaceuticals, medical devices, healthcare and chemicals industries as Senior Trade Adviser of UK Trade and Investment in Japan, ie the world second largest market in terms of sales of pharmaceuticals and medical devices. Hitomi joined the British Consulate-General in 1991, since then supported a large number of British companies’ successful entry to the Japanese market by utilising her local network and marketing expertise.


Hitomi NakaiSenior Trade Adviser (Life Sciences), UKTI Japan

Matt Newman is the national Life Sciences Sector Manager for UK Trade & Investment. Utilising the skills from his private sector background Matt has worked extensively on the international agenda with UK life sciences companies for over ten years. Matt has an in depth knowledge of the make up of the UK sector and continues to work collaboratively to develop a number of high profile sectoral strategies which enhance HM Government’s export focused agenda.


Matt NewmanSector Manager UK & Australasia, UKTI

Philip is a highly experienced pharma senior executive who has brokered over 60 collaboration deals via his past leadership of European partnering for Eli Lilly, and in management consultancy. Philip has extensive knowledge of the European pharma and investment environment and of innovative risk sharing models. He is currently MD of an expert consultancy advising on BD & Licensing, drug development, business planning and grant/investment approaches- and is currently working with several UK and European VCs, biotechs and academic groups.

Philip OliverManaging Director, Sevastopol Advisors Ltd

Session: Plenary Session

Robert Miller is CEO of Phynova Group Ltd, a life science company located near Oxford that develops plant-derived drugs, medical foods and functional ingredients. He has 30 years experience in the natural products industry in America, Europe and China. He has broad experience in the areas of product development, manufacturing, quality control, and regulatory affairs relating to natural products. In 2006 he established a Joint-Venture research company, Botanic Century Ltd at Zhongguancun Science Park, Beijing.


Robert MillerCEO, Phynova Group

18 Speaker Profiles

Dr Richard Pither is CEO of Cytox Ltd. Richard has driven the development of diagnostic and therapeutic products for over twenty years and held senior R&D and leadership positions in global Pharmaceutical companies including GE Healthcare (Medical Diagnostics), UCB-Celltech, Lorantis and Amersham plc.. Richard has a BSc in Cellular and Molecular Pathology from Bristol University. His PhD, also at Bristol, was gained in the field of immunology and vaccine design, followed by post-doctoral research at Harvard.


Dr Richard PitherCEO, Cytox

Jennifer Pierce is a partner at Charles Russell and heads its commercial intellectual property group. She advises on IP protection and strategy together with all forms of IP and commercial agreements relating to life sciences. She is included in IAM’s global list of patent and technology licensing specialists. Jennifer began life sciences work at BTG, where she advised on licensing and was a member of the team that floated the company. Since returning to private practice, she has worked with a variety of life sciences organisations, ranging from major pharmaceutical licensing companies to spin-outs to Governmental organisations.


Jennifer PiercePartner, Charles Russell

Thomas is Director Business Development at ICON clinical research, a full service CRO and leading medical imaging service vendor. Thomas works for more than 10 years in medical imaging and clinical research in different imaging CROs. He is a trained biochemist with many years of pre-clinical research in academia and Biotech. He managed more than 30 medical imaging studies and gained significant experience in CNS clinical studies: e.g. Alzheimer´s disease, stroke, glioblastoma, brain hemorrhage.


Keith has been in Biotechnology since it started. Having worked for GSK and ICI/Zeneca in genetics/molecular biology he led several large groups including Discovery, finally running the patent group. He then left for the USA and worked in a company on the West Coast, Maxygen, leading the small molecule group through the IPO and growing a business which eventually spun out as “Codexis”. On coming back to the UK, Keith worked with a fund called BBSF and acted as CEO for several of the companies in the portfolio, including Spear, sold to Advent International. He led Domainex through a merger with NCE to form a successful business in protein structure-based chemistry. Polytherics was built through organic growth since 2005 to a company of >30 people. Keith is currently chairman of Domainex, Biomoti and Canbex and has a portfolio of other interests.

Session: Case Study 1 - AstraZeneca and Bristol Myers Squibb

Keith PowellChairman, Domainex

John ParkinsonDirector, CPRD and Corporate Executive Team, MHRA


Dr. John Parkinson is the Director of the all England, 53 million NHS observational data and interventional research service – the Clinical Practice Research Datalink (CPRD) that combined the services of the GPRD and Research Capability Programme (RCP). John became the first Director of CPRD at its launch in April 2012, and is also a member of the MHRA Corporate Executive Team.John gained his PhD in Biochemistry from the University of Liverpool.

Thomas Plath, PhDDirector, Business Development, ICON

19Speaker Profiles

Dr Savidge is currently Director, Business Development at Bicycle Therapeutics and was responsible for negotiating the company’s recent partnership agreement with Thrombogenics N.V., announced in September 2013. He has also recently acted as business development consultant to several biotech companies (including Syntaxin and ReNeuron). Prior to this he spent 5 years at Evotec having responsibility for partnering internal pipeline programmes in CNS and pain, executing two significant deals with Roche.

Session: Approaches to Partnering - Part I

Jonathan SavidgeDirector of Business Development, Bicycle Therapeutics

With over 14 years bioinformatics experience and a scientific background in molecular biology and immunovirology (PhD from the Pasteur Institute, France), Abel first got to grips with bioinformatics tools and code in the early 90s whilst working on viral phylogenetic studies. After his PhD, he joined the effort at Genoscope (Evry, France) in ramping up the human genome project, putting in place the automatic gene annotation system for human chromosome 14. In 2001, Abel moved to the European Bioinformatics Institute (Cambridge, UK) where he led the Ensembl comparative genomics team until 2007. He founded Eagle shortly before graduating from the Cambridge Judge Business School MBA program in 2008. For the last 5 years he has been a driving force within the executive team at Eagle, supporting the strategy and partnership activities as well as setting up a world-class company operation able to adapt to market demand. This has enabled the company to sustain its growth and extend its activities horizontally from the traditional pharma/biotech sector into sectors as diverse as plant breeding, animal health, consumer goods and food safety.


Able Ureta-VidalCOO and Founder, Eagle Genomics

Priya Varadarajan is the national lead for Life Sciences for UKTI in India. She is based in Bangalore, the biotech capital of the country. Priya is a Chartered Accountant by profession and gives UK SMEs the added advantage of the business side as well when she is advising them on markets and opportunities. Priya has helped over 100 UK SMEs over the last 6 plus years understand the potential of working with a huge market, helping access this complicated market and also easing out a lot regulatory hurdles through her fantastic networks and contacts.


Priya VaradarajanIndia Lead Life Sciences, UKTI India

Executive Chairman of Q-Chip a Cardiff based company developing novel delayed release formulations.His past roles include: Founder and CEO of Arrow Therapeutics Ltd (an antiviral drug discovery company acquired by Astra-Zeneca PLC for $150 million in February 2007).Professor of Cell Biology and Virology UCL.Head of Biology for the Wellcome Foundation Limited.Fulbright Fellow and Faculty member Baylor College of Medicine, Houston Texas.Over the last 15 years Ken has been involved in developing UK biotechnology companies utilising different business models. His companies have been involved in significant licensing deals with Pfizer, Novartis, Astra-Zeneca and GSK.

Session: Case Study 1 - AstraZeneca and Bristol Myers Squibb

Ken PowellExecutive Chairman, QChip

20 Speaker Profiles

Martin Welschof is the CEO of Opsona Therapeutics Ltd. a leading immunology drug development company, focused on novel therapeutic approaches to key targets of the innate immune system associated with a wide range of major human diseases, including inflammatory related disease indications, such as transplant rejection and cancer. The company was founded in 2004 by three world-renowned immunologists at Trinity College in Dublin.


Martin WelschofCEO, Opsona Therapeutics

Professor David Wyper is the Director of SINAPSE - www.sinapase.ac.uk - an academic pooling group, specializing in medical imaging, established by the Scottish Funding Council in 2007. Prior to this he was Director of the Department of Clinical Physics and Bioengineering and Associate Director of Research and Development in NHS Greater Glasgow and Clyde. He helped to establish Scottish Health Innovations Limited and was the SHIL Board’s NHS representative from 2002 -2010.

David WyperDirector, SINAPSE

Evelyne Vuaridel joined Debiopharm in 1994 where she works in the Business Development & Licensing department as New Opportunities Officer. In her current role she is responsible for the search and identification of novel therapeutic molecules in Europe, and the evaluation process up to due diligence.Prior to joining the scouting team, Evelyne Vuaridel spent 14 years in the company as a drug delivery expert. She held management positions in the development of controlled release formulations, advanced oral delivery formulations and nanotechnologies. During 3 years she was a research associate at the State University of New York and three years as the head of topical formulations at Zyma/Novartis.She holds a pharmaceutical diploma and a PhD from the ETHZ .

Session: Approaches to Partnering - Part I and II

Evelyne VuaridelSenior Evaluator Drug Delivery, Debiopharm

Guy has been CEO of Deontics Ltd for the last two years. Previously he was a practising surgeon, a clinical research physician at Eli Lilly, a Healthcare investment banker, CEO of Cancer Research Ventures (CRUK), and Chairman of Cambridge Cognition Ltd. Deontics Ltd. has world-leading clinical decision support technology originating from research carried out at CRUK, Oxford University and UCL.

Guy Wood-GushCEO, Deontics


Tristan Vaughan PhDSenior Director, Research, Antibody Discovery and Protein Engineering (ADPE), MedImmune


Tristan first joined Cambridge Antibody Technology (CAT) in 1993. Following the acquisition of CAT by AstraZeneca, he is currently responsible for generating around two thirds of the antibody portfolio for MedImmune, AstraZeneca’s biologics business. His teams utilises the core technologies of phage and ribosome display, as well as in vivo platforms to discover and engineer mAbs and, together with Protein Sciences and High Throughput Screening teams, support four disease areas. Prior to his current appointment, Tristan held key operational responsibilities as part of the successful CAT-AstraZeneca strategic alliance and prior to that for CAT’s Milestone and Royalty based Alliances, including that with Human Genome Sciences that delivered Benylsta®. He also developed the platform technology to build antibody libraries of > 1010 members and was also a key member of the team that discovered Humira®. Before joining CAT, he was a postdoctoral fellow at the University of Toronto. Tristan is a University of Leeds graduate from the Genetics Department.

21Speaker Profiles

22

Chair

Speakers

Panellists

Chair

Speakers

Panellists

Registration

Coffee Break

St James SuiteCase Study 1

AstraZeneca and Bristol Myers Squibb

11.15-12.15

Mike Ward SCRIP Intelligence

Shaun Grady AstraZeneca

Ken Powell Q Chip

Keith Powell Domainex

08.15-09.00

10.25-10.45

10.05-10.25

09.45-10.05

09.25-09.45

09.15-09.25

Enabling Clinical Research to Stimulate Growth Dr Louise Wood Department of Health

A Strategic Corporate Venture Fund Perspective on their Role in the Modern Biopharma Sector

Roel Bulthuis Head of Merck Serono Ventures, Merck Serono SA Wolfson Institute for Biomedical Research, UCL

An Academia-Industry Interface that Enables the Discovery of Innovative Medicines

Sir Salvador Moncada Professor of Experimental Biology and Therapeutics, UCL

The Industry in 2014: Predictions, Hopes and Fears Mike Ward SCRIP Intelligence

Westminster SuiteCase Study 2

ThromboGenics and Novartis

John Hodgson SCRIP Intelligence

Desire Collen ThromboGenics

Barbara Domayne-Hayman Stevenage Bioscience Catalyst and Autifony Therapeutics

Jennifer Pierce Charles Russell

David KennardGilead

Whittle RoomDeveloping Oncology

Biomarkers: Lessons from other Therapeutic Areas

Eddie Blair Integrated Medicines

Hanns-Georg Klein IMGM Labortories GmbH

Mohammad Afshar Arianan Pharmaceuticals

Albert SuiteNatural Product

Development

Greer Deal GRS

Meredith Lloyd-Evans BioBridge Limited

Robert Miller Phynova

Andrew Casey BIOTECanada

David Mackie Marine Biopolymers

12.15-13.30

10.45-11.15

08.00

Parallel Streams - Innovative Strategies to Bridging the R&D Funding Gap

Plenary Session

Opening of Genesis 2013 Harriet Fear One Nucleus

Life Science Manifesto 2015-20

Philip OliverSevastopol Advisors

Plenary Session Chair

Chair

Speaker

Panellists

Chair

Speaker

PanellistsAnsar Jawaid AstraZeneca

Richard Pither Cytox

Lunchtime Keynote Address

09.25-10.45

Sir Christopher Evans Excalibur Group

Programme

Chair Steve Bates BIA

St James Suite

Thomas Plath ICON

Michael Jackson Eisai

Speaker

23Programme

Coffee Break

Data Management in Healthcare Research

15.00-16.00

Abel Ureta-Vidal Eagle Genomics

John Parkinson CPRD

Guy Wood-Gush Deontics

Abel Ureta-Vidal Eagle Genomics

Steve Gardner BioLauncher

Staffan Gestrelius Capish Knowledge

Imaging in CNS

Mo Alavijeh Pharmidex

Kevin Cox Imanova

John O’Brien University of Cambridge

Approaches to Partnering

Evelyne Vuaridel DebioPharm

Antibody Based Therapeutics

John Burt Polytherics

Martin Welschof Opsona Therapeutics

Matthias Grossmann PAREXEL International GmbH

Tristan Vaughan MedImmune

14.30-15.00

St James Suite Westminster Suite Whittle Room Albert Suite

Coffee Break16.00-16.30

The SCRIP - One Nucleus Debate: The Industry in 2018: Predictions, Hopes and Fears 16.30-17.30



Shaun Grady AstraZeneca

Matthew Foy SR One

James Caan Hamilton Bradshaw


Chair

Speaker

Panellists

Chair

Speaker

Panellists

Speakers

Panellists

Flic Gabbay TranScrip Partners

Chair

Charles Brigden Amgen

Chair

Speakers

John AnsellTranScrip Partners

Charles BrigdenAmgen

Evelyne VuaridelDebiopharm

Case Study 3Astex and Otsuka


Case Study 4Ipsen and Syntaxin

Approaches to Partnering

Flic GabbayTranScrip Partners

UKTI Showcase Session

St James Suite Westminster Suite Whittle Room Albert Suite


Chair

Speaker

Panellists

Morris Berrie Tech Transfer Summit and Tech Investor

Susan Foster Mintz Levin

Harren Jhoti Astex Pharmaceuticals

Martin Buckland Astex Pharmaceuticals


Chair

SpeakerHelen Cohen Ipsen

Panellists

Neil Fish Norgine

Davidson Ateh BioMoti

Introduction

Speakers

UK Trade & Investment and Office for Life Science Investment will present the UK strengths

13.30-14.30

Chair

Whittle Room

Jonathan SavidgeBicycle Therapeutics

ChairMatt Newman

USA

India

John Maclennan

Priya Varadarajan

ChinaEmily Liang

JapanHitomi Nakai

Speakers

Cancer Research UK Catalyst Club 17.30 -17.40

Drinks Reception 17.40 -19.30

Rebecca Parkes Cancer Research UK

David Wyper SINAPSE

Adolfo Cotter NeuroImage

Georg Buchner Neill Mackenzie Roji Life

Matthew Foy SR One

John Ansell TranScrip Partners

Panellists

1

Lift

s

Lift

s

Lifts

Cate

ring

Catering

Part

nerin

g

666260

575655

58 59

8180

7776

74

7

810

11 912

1314

1617 15

18

43

44

46

47

4548

3

2

6

5

14

24

23

21

20

2219

5150

Bio

Cafe

6869

7082

Whi

ttle

Roo

m

Benj

amin

Bri

tten

Ro

om

Catering

Cate

ring

Help Desk

Flem

ing

Room

Catering

65 6675

83

71 6463

614949a

7879

Refr

eshm

ents

Tale

nt L

oung

e

Press Room

25A4P Bioanalytical Group

Alpharmaxim

Andrew Porter

APL

Arkivum Limited

AstraZeneca

Boyd Consultants

Canadian High Commission

Charles Kendall BioLogistics

Cogent SSC

Cryostore

Dora Wirth (Languages)

Dundee Cell Products

Eagle Genomics

Edinburgh BioQuarter

Enterprise Europe Network

ERA Consulting

First Sight Media

Flanders Investment & Trade

Flanders House Forresters

Gregory Fryer Associates

Greiner Bio-One

Harlow District Council

Illingworth Research

KISS Communications

LES

Locate in Kent

London & Partners

London Life Science

Mathys & Squire

MedGenesis

MRC Technology

Naturejobs

NIHR Biomedical Research Centre,Oxford

Norwich Research Park

Novasecta

Ontario Ministry of Economic Development

Pharma Training International

Pharmaterials

Pharmidex Pharmaceutical Services

Pharma Publications

Phastar

Public Health England

QuickSTAT

Scottish Development International

SCRIP Intelligence

Simbec Research

Society of Biology

Stockholm-Uppsala

TranScrip Partners

UbiFrance

UKBIF

UKTI

UMI3

Welsh Government

World Courier

44

56

46

45

66

63

47

17

75

70

76

77

16

43

7

20

67

55

49

49a 50

2

12

24

80

64

14

69

78

71

8

4

5

82

21

13

9

18

83

81

62

68

19

57

48

6

58/59

65

74

15

1

3

10/11

22/23

51

60

79

pExhibitor List

1

Lift

s

Lift

s

Lifts

Cate

ring

Catering

Part

nerin

g

666260

575655

58 59

8180

7776

74

7

810

11 912

1314

1617 15

18

43

44

46

47

4548

3

2

6

5

14

24

23

21

20

2219

5150

Bio

Cafe

6869

7082

Whi

ttle

Roo

m

Benj

amin

Bri

tten

Ro

om

Catering

Cate

ring

Help Desk

Flem

ing

Room

Catering

65 6675

83

71 6463

614949a

7879

Refr

eshm

ents

Tale

nt L

oung

e

HIGHEST DENSITY OFBIOTECH COMPANIESWORLDWIDE *

Join us for the session with the eminent Professor Désiré Collen about the deal between Flemish company ThromboGenics and Novartis and find out how the biotech focussed business environment in Flanders has provided the fundamentals.Venue: parallel stream in the St. James Suite on floor 4 at 11.15am.

Find out what Flanders can do for you and your company and visit us at our stand!

www.investinflanders.com

FLANDERS, BELGIUM

(*) according to new Scientist magazine 2012

Flanders Investment & Trade | 1a Cavendish SquareGB-London W1G OLD | United KingdomT +44 20 73 07 77 10 | [email protected] | twitter.com/InvestFlanders

Adv_GenesisConferentieUK2013_200x287.indd 1 21/10/2013 17:15:54

The Genesis Talent Lounge

The Talent Lounge One Nucleus is delighted to introduce a new addition to Genesis 2013, the Talent Lounge which is a dedicated area for careers, training and recruitment for company executives, academic researchers and advisers to interact. The Talent Lounge is where providers and advisers in the area of skills, recruitment and training can be accessed by delegates.

It is an often used phrase that ‘people are our biggest asset’, but do you develop your company’s human capital effectively?

• What skills gaps you feel are hard to fill?

• What training courses are available to life science research and business executives?

• Are you using the optimal recruitment strategy to find the right people?

• What career opportunities does the life sciences sector offer?

• Does your science writing get the message across?

The Genesis 2013 Talent Lounge will have experts from Nature, Cogent, Pharma Training International, HRS, UCL, Queen Mary University, Sciad, Birkbeck University, George James, the University of Cambridge and the Society of Biology available to answer and discuss any of the above questions in a non-sales environment.

27

VISIT THE FRENCH PAVILION

FLEMMING ROOM - STAND 3

For the 2013 edition of Genesis, Ubifrance has once again brought together a delegation of French companies working in the life sciences sector. Hosted on the Ubifrance stand in the Flemming Room, the French companies will be promoting a range of products and services in the biotechnology and pharmaceutical sector. These companies are looking to reinforce their professional contacts and explore new partnering opportunities between France and the UK.

UBIFRANCE, the French agency for international business development lies at the heart of France’s public sector export support framework.

The London office of the French Trade Commission Ubifrance promotes trade and business development between France and the UK. It offers a range of services to French companies including B2B events, conferences, networking opportunities and individual partnering services.

Come to stand 3 in the Flemming Room to meet with the French delegation, or pick up one of our catalogues at the event. Should you wish for more information, please use the contact details below. We look forward to meeting you at Genesis 2013 and wish you a successful event.C o n t a c t : K a t i e D o c w r a , T r a d e D e v e l o p m e n t A d v i s e r ,H e a l t h c a r e a n d B i o t e c h n o l o g y S e c t o r K a t i e . d o c w r a @ u b i f r a n c e . f r

For our programme of events visit our website: http://www.ubifrance.com/uk

APL is a leading Contract Development and Manufacturing Organisation within Scandinavia. We have been established for over 30 years with four production sites in Sweden that offer services that cover the entire development process. We specialise in both sterile and non sterile manufacturing of biopharmaceuticals and pharmaceuticals along with drug product formulation development and analytical method development. APL is highly flexible, we are also very dedicated to our customers and we can help you with a small project right up to manufacturing your product. Our facilities are fully cGMP compliant and are regularly inspected by EMA, FDA, customers corporate QA.

Mattias Nyström, Business Development [email protected] or ([email protected]) www.apl.se/enStand 45

AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit: www.astrazeneca.com.

Gerhard Symons [email protected] Stand 63

A4PBio provide CRO oversight, project management and consultancy services in order to deliver regulatory compliant bioanalysis and bio-logistics solutions to the life science sector. A4PBio offer client-focused solutions in global laboratory selection, through assay development and validation, study sample analysis, data reporting and document review. Combining this with bespoke logistics solutions for the pro-actively managed transport of time and temperature critical biological samples and cell-based therapies.A4PBio’s flexible and scalable resources, using considerable Pharmaceutical, Biotechnology and CRO experience, deliver individually built, cost effective, scientifically robust and regulatory compliant outsourcing or consultancy solutions.

www.A4Pbio.com Stand 44

31Exhibitor Profiles

Andrew Porter Limited is a laboratory relocations specialist and the only company in the sector in Europe to adopt GxP standards. The need to relocate equipment is integrated with the movement of temperature controlled materials, data and dangerous goods as part of an overall lab relocation package. The firm understands the post move IQ/OQ/PQ requirements, with every move focused toward the most efficient and effective uptime sequencing requirement. With its fleet of more than 60 vehicles, the firm provides professional support to organisations operating across the European life sciences landscape, as well as further afield using its extensive network of worldwide partners.

John Best, European Sales Director [email protected] 46

Arkivum provide a large scale, long term, cost effective data archiving service with a unique 100% data integrity guarantee.With large volumes of data - which are growing year on year - which need to be retained, organisations face ever increasing storage costs as they retain this archive data on expensive media such as disk.Arkivum’s full managed service provides an elegant, low cost, highly secure and easy to use solution to these challenges.The reductions in capital expenditure, improvements in operational efficiency and the certainty of compliance means that our clients see significant benefits in a very short time-scale.

Cathy Brode, Business Development Manager and Head of [email protected] 66

Alpharmaxim “Words are…the most powerful drug…” Kipling.

Whether to enhance investor appeal, demonstrate the place for your product, add value to customers or increase attraction to investigators, the need for clear communication has never been greater particularly in speciality areas. Alpharmaxim are experts at helping you maximise the science behind your brands. We focus on speciality healthcare clients, where the need to change beliefs is paramount, and clearly communicate value through science to all stakeholders. We take time to understand your needs and to provide tailored recommendations that will truly meet them. Our communications truly are your most powerful drug!

Will Hind [email protected] Stand 56

No more capacity worries

• Experiencingfluctuationsindemandinyourbioinformaticsteam?

• Wanttotestanewideaortechnology?

• Seensomethinginterestingintheliteratureandlackingthetimeorresourcestotryitout?

• Projectdeadlineapproaching,butdon’thaveenoughstafftodeliver?

Pre-purchased, guaranteed availabilityRecruitingandretainingabioinformaticsteamwithsufficientexperienceandappropriateskillscanbeaheadache–sowhynotoutsource?

Wearebioinformaticsexpertswhoworkonanytaskunderthesunthatrelatestogenomicdataorplacingdataintothecontextofthegenome.

AdedicatedEaglebioinformaticianisassignedtotheprojecttoactasasinglepointofcontactandhasinstantaccesstoourentireteam’sknowledgeandexperience.

Eagle’son-demandserviceisavailableonyoursiteorremotely.Itisidealforgettingassistancewithprojectsthataretoosmallorlooselydefinedtobeabletospecifyinfullfortraditionaloutsourcing.

•Short-noticeaccesstoexpertise

•Bunchtheworktogetherorspreaditout

•UseEaglestaffonlywhenneeded

•Utiliseourexpertiseforanythingfromexploringnewresearchideastomaintenancetasks

•Eagle’sconsultantsallhavemanyyears’experienceinbioinformatics

Example usage: 6 0 hours over 6 months

Eagleon-demandBioinformatics expertise when you need it

BALANCEBALANCEBALANCEBALANCE

USAGEUSAGEUSAGEUSAGEUSAGE BALANCE

-4 Top up time!

20

10

3

7

7

4

2

65 55

27

17

14

7

0

4947

MAR1 2 3 4 5 6

7 8 9 10 11 12

13 14 15 16 17 18

19 20 21 22 23 24

25 26 27 28 29 30

31

APR1 2 3 4 5 6

7 8 9 10 11 12

13 14 15 16 17 18

19 20 21 22 23 24

25 26 27 28 29

MAY1 2 3 4 5 6

7 8 9 10 11 12

13 14 15 16 17 18

19 20 21 22 23 24

25 26 27 28 29 30

31

JUN1 2 3 4 5 6

7 8 9 10 11 12

13 14 15 16 17 18

19 20 21 22 23 24

25 26 27 28 29 30

JUL1 2 3 4 5 6

7 8 9 10 11 12

13 14 15 16 17 18

19 20 21 22 23 24

25 26 27 28 29 30

31

[email protected] www.eaglegenomics.com +44 (0)1223 654481

0283_2012_Elastic A4.indd 1 12/10/2012 10:39

The Cogent Group comprises Cogent SSC, The Cogent Technical Apprenticeship Service and The National Skills Academy for the Process Industries. Cogent Group Companies work in an alliance with employers to develop, design and deploy skills and education solutions for the science industries.The approach is evidence-based and employer-led, with the ambition to boost sector innovation, growth, and competitiveness through skills. Cogent Group skills solutions are adopted by every size of organisation, from SMEs through to global companies. Cogent works right across the science sector including life sciences and industrial science.

www.cogent-ssc.com Stand 70

At Charles Kendall BioLogistics, we choose not to be all things to all men, which is what makes us unique in our field as an Events Logistics company in the Pharma and Life Sciences market sector. We offer our clients a complete and dedicated door-to-door exhibition service. Working closely with our overseas offices and agents, we will continue to support British exhibitors at Pharma & Life Science events throughout the world. Working in close co-operation with our parent company, Charles Kendall Freight, we are able to offer all our exhibition clients a tailor made solution to any event, anywhere in the world.

Michael [email protected] http://www.charleskendallfreight.com/freight/exhibitions Stand 75

Canadian High Commission The Canadian Trade Commissioner Service is a network of more than 1000 trade professionals working in Canadian embassies, high commissions, and consulates located in 150 cities around the world and with offices across Canada. The Trade Commissioner Services in London helps companies that are looking to trade, invest or develop innovation and R&D partnerships. We provide advice, vital contacts, market information and other services in order to facilitate trade between Canada and UK.

Amir Golbang, PhD, Trade Commissioner, Healthcare & Life Sciencesamir.golbang@international.gc.cawww.tradecommissioner.gc.ca/eng/home.jspStand 17

No more capacity worries

• Experiencingfluctuationsindemandinyourbioinformaticsteam?

• Wanttotestanewideaortechnology?

• Seensomethinginterestingintheliteratureandlackingthetimeorresourcestotryitout?

• Projectdeadlineapproaching,butdon’thaveenoughstafftodeliver?

Pre-purchased, guaranteed availabilityRecruitingandretainingabioinformaticsteamwithsufficientexperienceandappropriateskillscanbeaheadache–sowhynotoutsource?

Wearebioinformaticsexpertswhoworkonanytaskunderthesunthatrelatestogenomicdataorplacingdataintothecontextofthegenome.

AdedicatedEaglebioinformaticianisassignedtotheprojecttoactasasinglepointofcontactandhasinstantaccesstoourentireteam’sknowledgeandexperience.

Eagle’son-demandserviceisavailableonyoursiteorremotely.Itisidealforgettingassistancewithprojectsthataretoosmallorlooselydefinedtobeabletospecifyinfullfortraditionaloutsourcing.

•Short-noticeaccesstoexpertise

•Bunchtheworktogetherorspreaditout

•UseEaglestaffonlywhenneeded

•Utiliseourexpertiseforanythingfromexploringnewresearchideastomaintenancetasks

•Eagle’sconsultantsallhavemanyyears’experienceinbioinformatics

Example usage: 6 0 hours over 6 months

Eagleon-demandBioinformatics expertise when you need it

BALANCEBALANCEBALANCEBALANCE

USAGEUSAGEUSAGEUSAGEUSAGE BALANCE

-4 Top up time!

20

10

3

7

7

4

2

65 55

27

17

14

7

0

4947

MAR1 2 3 4 5 6

7 8 9 10 11 12

13 14 15 16 17 18

19 20 21 22 23 24

25 26 27 28 29 30

31

APR1 2 3 4 5 6

7 8 9 10 11 12

13 14 15 16 17 18

19 20 21 22 23 24

25 26 27 28 29

MAY1 2 3 4 5 6

7 8 9 10 11 12

13 14 15 16 17 18

19 20 21 22 23 24

25 26 27 28 29 30

31

JUN1 2 3 4 5 6

7 8 9 10 11 12

13 14 15 16 17 18

19 20 21 22 23 24

25 26 27 28 29 30

JUL1 2 3 4 5 6

7 8 9 10 11 12

13 14 15 16 17 18

19 20 21 22 23 24

25 26 27 28 29 30

31

[email protected] www.eaglegenomics.com +44 (0)1223 654481

0283_2012_Elastic A4.indd 1 12/10/2012 10:39

33

Cryo-Store is a dedicated facility for the storage of biological material, disaster recovery material and research libraries in a totally secure temperature controlled conditions. It provides an invaluable resource for the biotechnology, pharmaceutical and medical industries.Our storage temperatures range from ambient to liquid nitrogen.The facility is GxP compliant and is continuously monitored and alarmed, ensuring sample temperatures are consistently maintained. Full emergency back-up systems are constantly on stand by, covering storage units, power supply and data.Cryo-Store is licenced by The Human Tissue Authority (HTA) and for the storage of GMM.

Malcolm Wilkinson [email protected] 76

DWL is a specialist translation service provider for the pharmaceutical industry providing translation solutions, in a wide range of languages for both traditional and emerging markets and clinical trial sites, in the fields of:REGULATORY AFFAIRS,CLINICAL RESEARCH, PHARMACOVIGILANCE,MEDICAL RESEARCH,MANUFACTURING, MEDICAL DEVICES,MEDICAL PUBLISHING ANDMARKETING COMMUNICATIONS. With over 50 years of experience, DWL has developed a solid, trustworthy and cost-effective service.

Samuel J. Wirth, Managing DirectorKim Shouler, Business Development [email protected] 77

Exhibitor Profiles

Boyd Consultants was established in 2005 and provides a range of expertise and skills central to the development of pharmaceutical & biotechnology medicinal products and medical devices. We are based in the UK with offices located in Cheshire and Cambridgeshire.Our consultancy services offer a cost-effective solution for those requiring expert assistance in order to expedite development, add value to their product, and reach those milestones. Professional Services• Product Development• Regulatory Affairs• Regulatory Medical Writing• Statistics and Data Management• Medical Monitoring Support• Business Support• Training

Prof Alan Boyd, Managing Director [email protected] 47

ABOUT FLANDERS

In Flanders when we’re hungry we make waterzooi.

We make fashion for Paris and endives for New York.

We make cinema, theatre and the best loved chocolate in the world.

We make the finest beers and the best medicines for headaches.

We make bicycles and champion cyclists.

We make history and the future.

We make patients feel better and people feel at home.

We make that everybody understands us.

We make steel cord and lace.We make video screens larger and energy greener.

We make the tallest towers and islands in the sea.

When we want to cheer ourselves up we make funny costumes and have a parade.

We make literature and architecture.We make scientists creative and craftsmen innovative.

We make music and the stages to perform it on.

In Flanders we make anything.We just don’t make a lot of fuss.

FLANDERS – IMAGINATION WORKSFlanders is the autonomous northern region of Belgium with Brussels as its capital.

It is the gateway to Europe.

35

Richard Holland, CBO [email protected] 43

Eagle is an expert provider of bioinformatics consultancy across a wide range of commercial sectors, covering human health, plant sciences, food, animal health, and consumer products. Through its multidisciplinary team headquartered in Cambridge, UK, Eagle can provide innovative and proven end to end solutions to support all of your bioinformatics research needs.The Eagle team are experts in a range of bioinformatics tools for both the commercial and academic sectors, and are able to provide an impartial opinion on the most effective approach for your problems. As well as the application of bioinformatics tools and technologies, Eagle is active in developing and improving them through a number of commercial and academic collaborations, such as Ensembl, Taverna and TraitTag. Eagle’s client base covers the globe, including Europe, US and the Far East.

Adam Levy, Business [email protected]: 67

ERA Consulting has served the biopharmaceutical industry for over 25 years providing regulatory, strategic and technical guidance for the development of medicinal agents (>450 to date), including recombinant protein/antibody therapeutics, vaccines, ATMPs (cell/tissue/gene therapies), natural products and small molecules. Our consultants are drawn from biotech, pharma, biomanufacturing, regulatory, translational medicine and academic scientific backgrounds to provide experienced support from product inception through development to commercialisation. Services offered also include regulatory training and specialist due diligence. With offices in London, Washington D.C, Germany and Australia, ERA maintains a global presence and interacts closely with European, US and other regulatory authorities.

Edinburgh BioQuarter is a unique concept, bringing together scientists from the University of Edinburgh and NHS Lothian with commercial research companies to collaborate and accelerate the development of new drugs, diagnostic tools and medical devices to treat diseases. This enterprise has made Edinburgh a leading European destination for translational medical research. 6 years ago the University joined forces with Scottish Enterprise and NHS Lothian to create the Edinburgh BioQuarter. Its aims were to foster deeper links with industry through collaborative research; to create new companies based on Edinburgh’s research base, and to encourage a culture of commercialisation in the NHS and among academic researchers. An experienced Commercialisation Team was established in 2010 to deliver these aims and in just over three years has spun out seven new life sciences businesses and negotiated a number of major industrial collaborations, as well as generating 100 new product or business concepts from its Innovation Competition.Shona Cameron, Head of Marketing and Communicationsshona.cameron@bioquarter.comwww.bioquarter.comStand 7

First Sight Media are a video production company that will help you to reach your customers and target an audience with a message that engages and informs. For over 20 years we have delivered creative live event, training and promotional video productions and as a result have built up an experienced and dedicated team of media professionals who pride themselves in exceeding client requirements.Online is our forte and we excel at live and on-demand video streaming. This is enhanced for conferences and webinars through our bespoke presentation software iPresenter, allowing us to deliver high definition video of your speaker simultaneously with their presentation slides across the internet. Please visit our website which contains many examples of our work together with testimonials supporting the services we provide.

Steve Webber, Business Development Managerstevewebber@firstsightmedia.co.ukwww.firstsightmedia.co.ukStand 55

Exhibitor Profiles

Enterprise Europe Network is your gateway to competitiveness and innovation. The Network supports businesses to make the most of the opportunities in the European market. We help local organisations to find the right business partners, build their innovation capacity and meet their capital requirements.Enterprise Europe Network is strong of approximately 600 business support organisations in 54 EU and non-EU countries, promoting international cooperation locally.Our services are specifically designed for Small and Medium-sized Enterprises (SMEs) but are also available to all businesses, research centres and universities across Europe.

Chris Farmakis, EC Funding Manager [email protected] 20

Dundee Cell Products Ltd (DCP) is a dynamic and innovative bioreagents and life science services company that commercialises high quality research tools for biochemistry, molecular biology and cell biology research and provides services in these areas to the life sciences community, including researchers in the pharmaceutical industry, biotechnology companies as well as in academic research institutions. Key proteomics-based technologies dedicated to assist the development of safer drugs quicker include ToxProfile, BioMarkId, PhosProfile and TargetId and are delivered through Dundee Cell Proteomics a division of the company.

Dr Paul Ajuh (CEO) or Dr Chloe Steels, Account Manager & Technical [email protected]@dundeecellproducts.comwww.dundeecellproducts.comStand 16

36

At Forresters, we provide clear, sensible and practical advice on intellectual property, including patents, trade marks, designs and copyright, in the UK and across the world. We like to take a collaborative approach with our clients, drawing on their knowledge to ensure that we understand what they want to achieve.We look to deliver our guidance in plain, jargon-free language and are not afraid to recommend a particular course of action, if we think it is right for you.We have a well-established and sizeable life-sciences department, with extensive experience in getting and litigating patents in the UK and Europe.

Charlotte Teall [email protected] 50

Angela Bonich, Director, Business Development [email protected] www.gf-associates.co.ukStand 2

GFA is an expert consultancy and services provider to the pharma and biotech industry, providing innovative, world class Regulatory, Clinical Research, Quality and Pharmacovigilance solutions to get your products to market. Our team of 30 experts with experience gained in a variety of industry backgrounds will provide you with bespoke, comprehensive development programme services; as part of a full plan or stand-alone services, to meet your commercial objectives. This year, we are celebrating our tenth anniversary and anticipate further growth and continued success in providing early phase clinical services and regulatory services across the product development process from pre-clinical to post marketing.

Greiner Bio-One is a high quality manufacturer and supplier to the Life Science, Pharmaceutical, Diagnostic and Clinical markets. We offer a vast portfolio of products for research and clinical applications.

The Bioscience product range provides highly innovative and novel solutions within laboratory plastics, combining 50 years of manufacturing knowledge with the latest technology and research.

The Preanalytics division focus on primary specimen collection for clinical applications and is one of the worlds leading providers of evacuated blood collection systems.

James Siddorns, Business Development [email protected] 12

Harlow Council is leading the development of the Harlow Enterprise Zone which will be providing space focussed on the needs of the Life Science sector. Uniquely located between London and Cambridge and with excellent access to Stansted Airport, talk to us about locating at the Harlow Enterprise Zone and the benefits for your business which include:Business Rates discountsSimplified PlanningAccess to innovation support through the Anglia Ruskin University’s Med Tech Campus.An exceptional and well connected location at the heart of the London Stansted Cambridge Corridor.

Andrew Bramidge, Project Director – Enterprise [email protected] www.harlow.gov.uk Stand 24

Exhibitor Profiles

Geert De [email protected]/londonStand 49

Flanders HouseFlanders is a dynamic and prosperous region within Belgium, in the heart of Europe. As a devolved nation, Flanders has a lot of autonomy and responsibilities, like in the field of health care, economic development, research and innovation policies. Flanders belongs to the top when it comes to health care and new technologies. Flanders’ Care, our overarching strategy for the health care sector, aims to constantly upgrade our care system through innovation and entrepreneurship. No wonder that Flanders is a leading life sciences region with several life sciences hubs. Today, biotech companies, research centres and bio incubators flourish in state of the art science parks clustered around our largest universities. Like previous years and with the support of the Representation of the Government of Flanders in the United Kingdom (Flanders House), several Flemish universities and research centres are present at Genesis to showcase their work and look for collaborations with British partners.

Flanders Investment and Trade is a government development agency at the Belgian Embassy in London. We provide confidential expert advice on doing business on the European continent. Our services are tailored to your business needs and are free of charge. We can help you find the right location and get you in touch with the right specialist or partner. Flanders Investment and Trade will guide you through our tax incentives and available grants to maximise opportunity. Feel free to contact us on [email protected] or +44 (0)207 307 77 10 regarding any query on doing business in Europe.

Geert De Proost, Representative of the Government of Flanders [email protected]/londonStand 49a

37

Illingworth Research is a unique, leading European Contract Research Organisation (CRO) offering a full range of clinical development services and medical photography services to the pharmaceutical, healthcare, biotechnology and medical device industries.ResearchNurses.co our sister organisation specialise in the provision of highly experienced research nurses for both on-site and homecare projects for the pharmaceutical, healthcare, biotechnology and medical device industries. We have over a decade of experience providing research nursing support to clients, and are now the UK’s leading independent research nurse provider.

Kieran Casey, Director of Business Developmentinfo@illingworthrsearch.comwww.illingworthresearch.comStand 80

Locate in Kent. Kent has a vibrant life science cluster of more than 130 companies employing more than 6,000 employees, with more than 50 of these in the MedTech sector. Companies such as Abbott, Aesica, DiaSorin, Novartis and Smiths Medical benefit from the county’s location close to London, available skills, dedicated sites and facilities and finance and support. The Kent cluster offers many opportunities including investment, partnership working and company growth. Discovery Park Enterprise Zone offers 1.5m sq ft of dedicated state of the art laboratories and specialist space, and is already home to 40 companies including more than 20 life sciences companies such as Pfizer and Mylan, employing nearly 1,000 skilled staff. Paul Wookey, Chief Executive Locate in Kent, [email protected] www. locateinkent.comAnna Stone, Leasing Manager Discovery Park, [email protected], Stand 69

London & Partners is the official promotional organisation for London. Our company attracts and delivers value to business, students and visitors. We work in partnership with organisations across the world to achieve our goal – that London is recognised as the best big city on Earth. London & Partners connects international businesses to London, helping them set up, succeed and grow. Our expert and experienced professionals can advise you on every aspect of locating and doing business in London.www.londonandpartners.comStand 78

Mathys & Squire has over 100 years of experience in providing Intellectual Property services to UK industry. Our attorneys work across a number of technical disciplines, including biotechnology, pharmacology, healthcare & medical devices, and chemistry. We have a global track record in securing valuable Intellectual Property rights for universities, government, start-ups and spin-out companies. Our attorneys also specialize in freedom-to-operate and due diligence activities, and we are particularly proud of our extremely high success rate in both defending and challenging patents before the European Patent Office. Most importantly, we develop IP strategies that align with our clients’ commercial plans.

Dr William Johnson, Associate [email protected] 8

KISS is a creative communications agency built on the principle of keepings things simple. Simple is better. In an ever increasingly complicated world it’s needed more than ever. As a multi-disciplinary agency with deep experience in the life science sector our services include strategy and messaging workshops, branding, design, advertising, digital, exhibitions, bespoke communications, training and, in conjunction with our partner Zyme Communications, specialist life science PR and marketing.

www.kisscom.co.uk www.zymecommunications.co.uk Stand 64

Exhibitor Profiles

LES Britain & Ireland (LES B&I) is one of 32 member societies of the global umbrella organisation LES International (LESI) and is also one of the most active. It is the society for professionals and business people interested in licensing, the transfer of technology, and the commercialisation of intellectual property rights. The Society provides unique opportunities for multidisciplinary education and networking, locally and globally. Through regular meetings of council, committees and special interest groups, members of the society are kept abreast of national and European Commission legislative proposals. They can also become involved at international level, and they have the opportunity to contribute to debate on crucial topical issues. Conferences, regular meetings and special events in London and throughout the regions offer members excellent opportunities to explore licensing-related subjects and to meet fellow practitioners.www.les-bi.orgStand 14

38

Norwich Research Park is a major centre for bio and medical technology research, comprising a community of academic and commercial scientists. It encompasses world-class science research at bioscience institutes, the University of East Anglia (Medical and Pharmacy Schools, Biomedical Research Centre, Clinical Trials Unit) and the Norfolk and Norwich University Hospital. The Park offers access to state-of-the-art facilities and expertise. We have 3,800 sq m of mixed laboratory and office accommodation for start-ups and established companies. Our new hub building Centrum has a further 2,300 sq m and will open spring 2014.

Dr Matthew Hills, Business-Science Liaisonmatthew.hills@norwichresearchpark.comwww.norwichresearchpark.comStand 13

Duncan Young, Business Development Manager [email protected] 5

MRC Technology (www.mrctechnology.org) is an independent life science technology transfer charity, offering professional services to organisations within the academic, charity, biotechnology and pharmaceutical sectors globally. Services include IP management and research and development for diagnostics, small molecules and therapeutic antibodies. MRC Technology bridges the gap between basic medical research and commercialisation, helping early discoveries progress to clinical application.

[email protected]: 82

Naturejobs is the global career resource and jobs board for scientists. We can help you throughout your job search and your career:• View science careers advice • Research employers • Set up job alerts • Upload your CV • Sign up to our newsletter • Search for jobs on your mobile • Interact via our blog Naturejobs provides a wide range of career advice, science recruitment news and science jobs, all free to access at naturejobs.com. Employers using the site range from top pharmaceutical and biotechnology companies to highly-respected academic and government institutions and charities. Take advantage of Naturejobs and grow your science career with us.

Exhibitor Profiles

Alex Prior, Business Development Manager [email protected] www.oxfordbrc.nihr.ac.uk and www.medsci.ox.ac.ukStand 21

The NIHR Biomedical Research Centre, Oxford is a partnership between the research expertise of the Oxford University Hospitals NHS Trust and Oxford University’s Medical Sciences Division supporting translational ‘bench to bedside’ research. Oxford is host to one of the largest Biomedical Research hubs in Europe recognized internationally for delivering outstanding teaching and research with global impact. Supported by significant investment into state-of-the-art facilities and research activities our scientists are consistently at the forefront of innovative research, from basic science through drug trials to clinical practice. We understand the value of collaboration and welcome the opportunity to build partnerships with industry, academia, medical organisations and charities.

London Life Science London has an active, highly concentrated and globally competitive life science sector incorporating numerous medical facilities, world leading academic institutions and a diverse range of companies. The city provides the perfect laboratory for research and development, producing unique opportunities for collaboration and investment.LondonLifeScience.com is a portal to help organisations navigate this complex research landscape. It creates an online interface between organisations in the capital, bringing the best life science minds together and encouraging collaboration, whilst competitively driving the sector forward. LondonLifeScience.com has been developed by London Medicine (a division of London Higher, the body representing higher education institutions within London). To learn more, follow us on Twitter @LondonLifeSci.Amy Lightstone, Project Manager, Lon-don Medicine [email protected] 71

MedGenesis Limited was formed to design, implement and market software solutions for the international pharmaceutical, medical device and cosmetic industries. Our lead product is the TARA (Tools for Adverse Reaction Assessment) system. Designed from the outset by pharmacovigilance professionals supported by experienced programmers, TARA offers a layout that is consistently simple, intuitive, user friendly and most importantly cost effective, making it suitable for all sizes of companies and academic units. TARA is currently deployed in several countries , and several follow up products are in late stage development.

Stephen Bentley, Director Mick Marks, Director [email protected] 4

39

Ontario, Canada The International Trade Branch of the Ministry of Economic Development, Trade and Employment is introducing the following Ontario companies to the Genesis Conference: BioScape Medical Imaging, BioPharma Services, KalGene Pharmaceuticals, NeuroImage and Sernova Corporation. These firms provide a wide range of services, technologies and products to the healthcare sector and share a reputation for quality and innovation.

Laurie D’Souza, International Market Consultant [email protected] 18

Grace Ong, Engagement Manager Euvian Tan, Senior Associatewww.novasecta.comStand 9

Novasecta is a resource-based strategy consultancy for life sciences companies.

We have worked with a diverse set of clients to create lasting value for their businesses in three areas:Research & DevelopmentCrafting R&D strategies, transforming R&D, achieving more from technology platforms and assets, actively managing R&D portfolios.CommercialBuilding go-to-market strategies, achieving more from commercial franchises, growing business units.CorporateCreating partnership strategies, deciding on M&A possibilities, enabling business development deals, securing financing.

Our specialist consultants all have prior professional experience from pharma, biotech, medical devices, CROs, scientific institutions, or life sciences consulting.

Exhibitor Profiles

PTI As part of Informa plc, the multinational publishing and conference company, Pharmaceutical Training International (PTI) is a bespoke training company providing interactive, up-to-date and topical courses, addressing the latest concerns facing the pharmaceutical and biopharmaceutical industry. With the experience of our Advisory Board we continuously revise our content to ensure that your course is relevant and timely. PTI also understands your work commitments, which is why we supply distance and on-site training courses for when time can be a precious commodity. Our programmes are delivered worldwide and have the flexibility to train small teams to larger organisations across multiple countries.

Pharma Publications is a dynamic media organisation, specialising in dedicated publications for the Life Sciences Industry. With a product portfolio of publications like, IPI - International Pharmaceutical Industry, JCS - Journal for Clinical Studies and JPC - Journal for Patient Compliance, we look into the best practice in outsourcing management for the Pharmaceutical & Bio-Pharmaceutical Industry. Providing peer-reviewed articles and analysis on drug discovery, drug development, clinical research, manufacturing, packaging, supply chain management, patient adherence and health outcomes, we provide comprehensive guidelines to help the industry grow. We endeavour to be your one-stop-shop for all your marketing to the industry.

Victoria Biscoe, Customised Training Consultant [email protected] Okullo Training Account Manager [email protected] www.pti-global.co.ukStand 83

Orsolya Balogh, Central Administrator [email protected], www.jforcs.com, www.jforpc.comStand 61

Pharmidex provides high quality experimental preclinical ADMET/PK data, critical to drug discovery programme progression. We have comprehensive in house laboratory facilities as well as bioanalytical laboratories at the Stevenage BioScience Catalyst. Extensive in-vitro & in-vivo assay options enable the provision of tailored studies to meet individual project needs. Through extensive knowledge of drug discovery and development, Pharmidex has been able to deliver a high level of customer satisfaction and forge several strategic international alliances, focussing on operations in the following areas: in vitro ADMET, in life, Pharmacology, CNS Drug Discovery, Bioanalysis, Metabolite Identification and Bioimaging.

Dr. Martin Barrett, Business Development [email protected] Stand 62

Pharmaterials is a contract service company providing pharmaceutical development for oral, inhaled, topical and parenteral routes of drug delivery with cGMP manufacturing for early phase clinical trials. Development work is underpinned by our comprehensive expertise in pharmaceutical materials science, salt selection, polymorphism, amorphous materials and formulation. We have a wealth of experience in the oral delivery of low solubility drug substances and have taken many formulations to the clinic.

Our core services:•Salt selection, polymorph screening and co-crystal formation.•Formulation development (Oral, IV, topical & inhalation).•cGMP manufacture of clinical trial material.•Solid state testing & Raman mapping of APIs, excipients and final drug products.•Amorphous quantification.

Christopher LandegDirector of Business Development [email protected] 81

40

SCRIP Intelligence - vital pharmaceutical industry ideas and global signals for your career, your business and your future.SCRIP Intelligence subscribers receive a glimpse of the future from the daily drumbeat of crucial events across the sector spectrum – from biotech start-ups to multinational giants; research boutiques to generic manufacturers; and suppliers large and small.Experienced writers and analysts are based in key geographic markets to convey all aspects of the industry. Global hot topics such as orphan diseases, personalised medicine, and management strategies from developed to emerging markets are covered with local depth and insight.

Paul Morkel, Marketing Manager [email protected]/freetrialStand 58 - 59

Scottish Development International is the economic development agency for Scotland and is a joint venture between the Scottish Government, Scottish Enterprise and Highlands & Islands Enterprise.Since it was founded 11 years ago, SDI has transformed Scotland’s economic outlook, attracting some of the world’s biggest companies to locate in the country, growing Scottish exports and creating over 19,000 new jobs.Scotland hosts one of the largest life science clusters in Europe with significant international presence in research, development and manufacturing. With a long and remarkable history of medical and scientific discovery stretching back 200 years, Scotland has always been at the forefront of medical innovation.

Simbec Research provides contract clinical trial services to the international pharmaceutical and biotechnology sectors, developing new medicinal products including devices and diagnostics. We have been servicing international pharmaceutical, biotechnology and related drug companies for over 35 years and specialise in First-in-Human studies of new molecular entities and biologicals. Trials conducted range from Phase I studies in healthy subjects through to Phase II trials in patients. All services are on one site, including full bioanalytical backup, Central Laboratory and related support services. Simbec is one of a select group of companies that has received Supplementary Accreditation from the MHRA.

Fiona Jefferson, International Senior [email protected] 6

Basia Kondratowicz, Senior Business Development Executive [email protected] www.simbec.com Stand 65

Exhibitor Profiles

QuickSTAT For over 30 years, QuickSTAT has played a critical role in managing clinical trial logistics for all phases of research and drug development. We specialise in global shipping of time and temperature-sensitive clinical research samples, investigational drugs, clinical trial supplies, and dangerous goods.Our long-standing clients include the leading pharmaceutical, biotech and clinical trial supply companies, CROs and central labs around the world.Our specialists are available 24/7, delivering complex logistical solutions and expert knowledge for your clinical trials.QuickSTAT has invested in leading edge, client-centric technology, uniquely designed to support clinical trial logistics.Gurmeet Sidhu, Business [email protected] Sarah Elliott, Business [email protected]@qintl.comhttp://quick.aero/quickstat Stand 48

Public Health England is an executive agency of the Department of Health. We operate a nationwide, integrated public health service through a network of over 5000 staff, working with and alongside others to protect and improve the public’s health and wellbeing and reduce inequalities.Public Health England combines the microbiology, diagnostics, research and manufacturing capabilities of the former Health Protection Agency with expertise in cancer and other aspects of health improvement and intelligence.We aim to be the authoritative national voice and expert service provider for public health ensuring everyone is protected from threats, providing products and services and working in partnership with the industry to deliver innovative healthcare solutions.

Business Development Department [email protected]/pheStand 57

Mohamed Hasham, Business Development Executive [email protected] 19

PHASTAR is a specialist CRO offering statistical consultancy and clinical trial reporting, by providing expert statisticians and programmers or managing and delivering in-house projects. Our number one priority is to ensure that the work we produce is of the highest quality: every project PHASTAR undertakes is supervised on methodology and utilises internal processes designed to ensure optimal quality. Services include production of TFLs, study design, modelling and simulation, advice on handling missing data across phase I to IV trials. We can manage and deliver whole clinical trial programs, or give you advice on a trial you are planning.

41

www.transcrip-partners.com Stand 1

TranScrip Partners is a rapidly growing cutting-edge contract organisation that supports biopharmaceutical product development and life cycle management. TranScrip Partners are strategic thinkers who do, and doers who think strategically. Working for more than 80 companies across 4 continents, TranScrip has shown it can play a crucial role in facilitating the selection and progression of drug candidates into clinical studies and on to POC, including demonstration of potential value, and, where necessary, securing funding and regulatory approvals. TranScrip’s expertise further extends across the design and implementation of clinical development plans, risk management, regulatory and product differentiation strategies.

The Society of Biology is a single unified voice for biology; advising Government and influencing policy; advancing education and professional development; supporting our members and engaging and advancing public interest in the life sciences. The Society represents a diverse membership of individuals, learned societies, and other organisations.

Stand 74

Stockholm-Uppsala is the region where business and research thrive! Our region is a hot-bed of creative cross-disciplinary collaboration and, together, we are building international businesses and delivering real research breakthroughs that will help solve the world’s health problems. We’re open-minded and productive. Our state-of-the-art infrastructure and talented scientists provide all the services and support you’ll need. www.suls.se.

Ola Björkman [email protected] Ywonne Bölja [email protected] Stand 15

UK Bio-Incubators offer flexible laboratory and office space, scientific and business support services to early stage and growing life sciences companies.The UK Bio-Incubator Forum (UKBIF) is a collection of Bio-Incubators located across the UK. The forum exists to promote the Bio-Incubators, share best practice and co-ordinate support for the life sciences early stage business community.

Miranda Knaggs, ChairMiranda.knaggs@stevenagecatalyst.comwww.ukbioincubation.comStand 10 & 11

UK Trade & Investment the Government department that helps UK based companies succeed in an increasingly global economy. Our range of expert services are tailored to the needs of individual businesses to maximise their international success. We provide companies with knowledge, advice and practical support. UK Trade & Investment also helps overseas companies bring high quality investment to the UK’s dynamic economy – acknowledged as Europe’s best place from which to succeed in global business. We provide support and advice to investors at all stages of their business decision-making. UK Trade & Investment offers expertise and contacts through a network of international specialists throughout the UK, and in British Embassies and other diplomatic posts around the world.

Matt Newman, Senior Sector [email protected] 22 & 23

Exhibitor Profiles

UBIFRANCE, The French Agency for International Development, promotes trade between France and the rest of the world, offering its clients a diverse range of customised services. Each office within the international network has specialised Trade Advisers working in various sectors to assist French companies with their commercial development strategies abroad. UBIFRANCE UK will be present at the 2013 edition of GENESIS on stand 3 with a delegation of French biotechnology companies looking to meet potential partners in the United Kingdom. For more details on the French delegation, please contact Katie Docwra.

Katie [email protected]. Stand 3

42

UMIP® is The University of Manchester’s agent for intellectual property commercialisation. UMIP’s three operational teams: Scouting; IP Development and Partnering; and Enterprise and Business Development are responsible for identifying, protecting and commercialising the University’s IP. UMIC® is the University’s Innovation Centre-its bioscience incubators include the successful Manchester Bioscience Incubator and the Core Technology Facility (CTF). UMIC® also provides conferencing and meeting room facilities. UMIP® and UMIC® are divisions of The University of Manchester Innovation Group Ltd; www.umi3.com.

[email protected] [email protected] 51

The Welsh Government’s Life Sciences sector team is focussed on business growth and commercial success. We are coordinating a strategy for the life sciences sector in Wales that enhances and develops our existing clusters of expertise and facilitates the creation of an ecosystem which is vibrant and dynamic. The team has access to a range of funding mechanisms and related programmes and infrastructure to support inward investment to Wales. We also have joined up routes across government departments to support academia and the NHS to pursue and share research excellence to benefit the economy and the people of Wales.

Mel Crisp, Head of New Business Development, Life Science Sector [email protected] www.wales.com/business Stand 60

World CourierIncorporated in 1969 World Courier is the largest and most experienced specialty courier with a network of over 152 company-owned offices, all ISO certified and GxP compliant. World Courier has set the benchmark for Bio-Pharmaceutical, time-sensitive transportation and is the acknowledged leader in delivering customised temperature-controlled solutions to the international bio-pharmaceutical industry. With in-house scientists to understand your needs World Courier can recommend, supply and replenish packaging and refrigerants to ensure the integrity of your temperature-controlled shipments. Documentation and regulatory requirements are managed to ensure your shipment complies with local requirements. We are dangerous-goods, Dry-Ice, liquid-Nitrogen and controlled-substance specialists.

David Spillett, Business Development Manager , Biopharm [email protected] 79

London : +44 (0) 20 7283 8989 Birmingham : +44 (0) 121 236 0484 Merseyside : +44 (0) 151 647 6746 Munich : + 49 (0) 89 2441 299 0 email : [email protected] website : www.forresters.co.uk

Patent and Trade Mark Attorneys We make it our business to understand yours Clear, straightforward advice for all your intellectual property issues

Exhibitor Profiles

ON Hub This newly launched One Nucleus initiative creates an opportunity for life science executives to accessmeeting space and office facilities at various life science hubs across the UK and further afield. Here theycan, for example, use WiFi and business services, have coffee and refreshments whilst meeting businesscolleagues by pre-arrangement or share a common interest when travelling.

Key Facts

Facilities are available to holders of an ON Hub membership card. The card is free to life science executives upon registration with One Nucleus.

Each card will be for the exclusive use of the holder and will carry a unique identificationHub locations will be listed on the One Nucleus website along with contact detailsON Hub members can contact an individual hub in advance to arrange access. Specific terms and conditions may apply that diffier from hub to hubAccess to a hub will require one additional form of photo ID to gain access to facilities

Participating Hubs

For more information about ON Hub, please contact [email protected].

One Nucleus, Granta Park, Cambridge

www.onenucleus.com

London & Partners, London Bridge, London

www.londonandpartners.com

London & Partners, the official promotional organisation for London, attracts and delivers value to business, students and visitors. The team works in partnership with organisations across the world to achieve the goal – that London is recognised as the best big city on Earth.

BioPark, Welwyn Garden City

www.biopark.co.uk

Located close to the heart of London’s biomedical technology community, BioPark provides specialist facilities and support for bioscience and health technology businesses, encouraging growth and the development of new products and technologies.

Life Sciences Hub Wales

An iconic building in Cardiff Bay will create the focal point for life sciences in Wales. The Hub is the place to meet people who know about life sciences in Wales and internationally.

The Hub will have great facilities for meetings, networking and events. The Hub will be the go-to place for life sciences businesses to start, develop and grow. To be launched on 5 March at BioWales.

Hilton Doubletree Allegiance Programme

www.hiltonsme.hiltonbusinessonline.com

Allegiance is a new programme from our support supplier, Hilton Doubletree, crafted specifically for SME businesses and offering savings when visiting any of the Hilton Worldwide portfolio.

Joining Allegiance is free and benefits are as follows:

10% saving on accommodation and 5% o meetings and events, food, drinks, WiFi, car parking and more

More than 100 hotels across the UK

Save money on business and leisure bookings

Network with other Allegiance members at exclusive events

Easy booking with our dedicated Allegiance portal and 24/7 reservations line

Simple to claim – simply present your Allegiance card at check out

Free to join and easy to save – just quote your Allegiance card number when you book

A dedicated meetings and events facilitator to help you and your perfect venue

Plus – Allegiance members can now enjoy 5% off at Living Well Health Clubs too!

43

London : +44 (0) 20 7283 8989 Birmingham : +44 (0) 121 236 0484 Merseyside : +44 (0) 151 647 6746 Munich : + 49 (0) 89 2441 299 0 email : [email protected] website : www.forresters.co.uk

Patent and Trade Mark Attorneys We make it our business to understand yours Clear, straightforward advice for all your intellectual property issues

ON Hub

Date:Date:

UK Trade & Investment is the government department that helps UK-based companies succeed in the global economy.

We also help overseas companies bring their high-quality investment to the UK’s dynamic economy, acknowledged as Europe’s best place from which to succeed in global business.

UK Trade & Investment offers expertise and contacts through its extensive network of specialists in the UK, and in British Embassies and other diplomatic offices around the world. We provide companies with the tools they require to be competitive on the world stage.

Come speak to our expert advisors at stand 22 & 23 in the Fleming Room. To find out more contact [email protected] www.ukti.gov.uk

Your Brilliant Ideas Our Insight

Genisis_brochure_v6.indd 2-3 22/10/2013 15:39

Join us at one of the largest UK Life Sciences conferences

6th & 7th March 2014Conference, Exhibition

and Partnering

Wales Millennium Centre, Cardiff, Wales

International speaker programmeFocus on delivering industry growth

1:1 Partnering meetings

Visit the website for more information and to register

www.biowales.com

WG20363 Welsh Government Genesis Ad.indd 1 21/11/2013 10:36

London’s premier Life Science & Healthcare networking conference

9 December 2014

Queen Elizabeth II Conference Centre

Westminster, London, UK

onenucleus.com/genesis

ON1038_Genesis_Ad_A4.indd 1 18/11/2011 14:20

genesis 2014

genesistogether we can transform patient care. find out more at johnson & johnson innovation...

Documents